Structure Therapeutics Total Debt vs. Net Income
| GPCR Stock | 66.55 0.92 1.36% |
For Structure Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Structure Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Structure Therapeutics American utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Structure Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Structure Therapeutics American over time as well as its relative position and ranking within its peers.
Structure | Build AI portfolio with Structure Stock |
Can Biotechnology industry sustain growth momentum? Does Structure have expansion opportunities? Factors like these will boost the valuation of Structure Therapeutics. Market participants price Structure higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Structure Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Structure Therapeutics requires distinguishing between market price and book value, where the latter reflects Structure's accounting equity. The concept of intrinsic value - what Structure Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Structure Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Structure Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Structure Therapeutics Net Income vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Structure Therapeutics's current stock value. Our valuation model uses many indicators to compare Structure Therapeutics value to that of its competitors to determine the firm's financial worth. Structure Therapeutics American is rated below average in total debt category among its peers. It is rated # 3 in net income category among its peers . Structure Therapeutics reported last year Net Loss of (110.27 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Structure Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Structure Total Debt vs. Competition
Structure Therapeutics American is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 515.9 Million. Structure Therapeutics maintains roughly 3.86 Million in total debt contributing less than 1% to equities under Health Care industry.
Structure Net Income vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Structure Therapeutics |
| = | 3.86 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Structure Therapeutics |
| = | (122.53 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Structure Net Income Comparison
Structure Therapeutics is currently under evaluation in net income category among its peers.
Structure Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Structure Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Structure Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Structure Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Structure Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.1 M | 1.1 M | |
| Net Interest Income | 41.4 M | 43.5 M | |
| Operating Income | -142.4 M | -135.3 M | |
| Net Loss | -110.3 M | -104.8 M | |
| Income Before Tax | -110 M | -104.5 M | |
| Total Other Income Expense Net | 41.4 M | 43.5 M | |
| Net Loss | -39.4 M | -41.4 M | |
| Net Loss | -110.3 M | -104.8 M | |
| Income Tax Expense | 356.5 K | 374.3 K | |
| Change To Netincome | 2.2 M | 1.6 M | |
| Net Loss | (2.68) | (2.81) | |
| Income Quality | 0.86 | 0.72 | |
| Net Income Per E B T | 1.15 | 1.11 |
Structure Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Structure Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Structure Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Structure Therapeutics' important profitability drivers and their relationship over time.
Structure Therapeutics Earnings Estimation Breakdown
The calculation of Structure Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Structure Therapeutics is estimated to be -0.34425 with the future projection ranging from a low of -0.595 to a high of 0.295. Please be aware that this consensus of annual earnings estimates for Structure Therapeutics American is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.59 Lowest | Expected EPS | 0.29 Highest |
Structure Therapeutics Earnings Projection Consensus
Suppose the current estimates of Structure Therapeutics' value are higher than the current market price of the Structure Therapeutics stock. In this case, investors may conclude that Structure Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Structure Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 15 | 54.45% | 0.0 | -0.34425 | -3.66 |
Structure Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Structure Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Structure Therapeutics American predict the company's earnings will be in the future. The higher the earnings per share of Structure Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Structure Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Structure Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Structure Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Structure Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Structure Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.27 | -0.37 | -0.1 | 37 | ||
2025-08-06 | 2025-06-30 | -0.26 | -1.89 | -1.63 | 626 | ||
2025-05-08 | 2025-03-31 | -0.25 | -0.82 | -0.57 | 228 | ||
2025-02-27 | 2024-12-31 | -0.28 | -0.21 | 0.07 | 25 | ||
2024-11-14 | 2024-09-30 | -0.27 | -0.2 | 0.07 | 25 | ||
2024-08-08 | 2024-06-30 | -0.24 | -0.18 | 0.06 | 25 | ||
2024-05-09 | 2024-03-31 | -0.21 | -0.19 | 0.02 | 9 | ||
2024-03-08 | 2023-12-31 | -0.21 | -0.5316 | -0.3216 | 153 | ||
2023-11-14 | 2023-09-30 | -0.29 | -0.62 | -0.33 | 113 | ||
2023-08-10 | 2023-06-30 | -0.28 | -0.6 | -0.32 | 114 | ||
2023-05-11 | 2023-03-31 | -0.41 | -0.25 | 0.16 | 39 | ||
2023-03-31 | 2022-12-31 | -0.82 | -1.14 | -0.32 | 39 |
Use Structure Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.Structure Therapeutics Pair Trading
Structure Therapeutics American Pair Trading Analysis
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Structure Therapeutics position
In addition to having Structure Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SRI Sustainable Growth Thematic Idea Now
SRI Sustainable Growth
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.